Table 1 Key model inputs
Mean | Distribution | 95% confidence interval | |
|---|---|---|---|
Cost parameters | |||
Multimodal screening (drop-outs) | £54 | Beta | £33 to £74 |
Multimodal screening (complete screening) | £61 | Hybrida | £37 to £83 |
Ultrasound screening (drop-outs) | £56 | Gamma | £29 to £92 |
Ultrasound screening (complete screening) | £61 | Hybrida | £31 to £100 |
Screening invitation (either strategy) | £2.09 | Gamma | £1.70 to £2.52 |
Diagnosis: Borderline | £110 | Gamma | £91 to £135 |
Diagnosis: Stage 1 ovarian cancer | £116 | Gamma | £90 to £133 |
Diagnosis: Stage 2 ovarian cancer | £126 | Gamma | £94 to £140 |
Diagnosis: Stage 3 ovarian cancer | £126 | Gamma | £102 to £152 |
Diagnosis: Stage 4 ovarian cancer | £112 | Gamma | £102 to £152 |
Treatment: Borderline | £3000 | Gamma | £1161 to £5696 |
Treatment: Stage 1 ovarian cancer | £6961 | Gamma | £4856 to £9438 |
Treatment: Stage 2 ovarian cancer | £7325 | Gamma | £5211 to £9795 |
Treatment: Stage 3 ovarian cancer | £9016 | Gamma | £6866 to £11,454 |
Treatment: Stage 4 ovarian cancer | £5892 | Gamma | £3823 to £8402 |
End of life cost: ovarian cancer | £7080 | Gamma | £5761 to £8533 |
Utility parameters | |||
Utility cancer free | 0. 900 | Beta | 0.325 to 1 |
Disutility Stage 1 ovarian cancer or false positive result | 0.200 | Beta | 0.044 to 0.437 |
Disutility Stage 2 ovarian cancer | 0.325 | Beta | 0.214 to 0.534 |
Disutility Stage 3 ovarian cancer | 0.413 | Beta | 0.329 to 0.600 |
Disutility Stage 4 ovarian cancer | 0. 455 | Beta | 0.413 to 0.601 |
Number of false positives per cancer identified | |||
Multimodal screening | 2.302 | Beta | 2.188 to 2.412 |
Ultrasound screening | 9.963 | Beta | 9.813 to 10.104 |